No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Antihypertensive Treatment with Losartan–Hydrochlorothiazide in Clinical Practice in Kagoshima
Rent:
Rent this article for
JPY
Abstract
Objective: To evaluate the effects of 12 months of antihypertensive treatment with losar tan –hydrochlorothiazide(HCTZ)in general clinical practice in Kagoshima, a Japanese prefecture with a high propor tion of persons aged ≧ 65 years and high prevalence of obesity(in Japan, body mass index ≧ 25 kg/m2). Methods and Results: In this multicenter collaborative open –label prospective observational study, 149 patients who failed to achieve target blood pressure(BP) with ≧2 months of antihypertensive therapy were switched to losartan 50 mg–HCTZ 12.5 mg. Ambulatory BP had decreased by 1 month(p<0.001); this effect continued throughout the study period. Almost 40% of patients achieved target BP by 3 months. The effects of losartan –HCTZ were not associated with antihypertensive agents used previously, coexisting diseases, or age. Uric acid(UA) decreased in patients with high baseline UA(≧7.0 mg/dL; p=0.004). No unexpected adverse events were reported. Changes in clinical laboratory values were mostly mild. Conclusion: Losartan–HCTZ is an effective and safe treatment option for clinicians treating aging and increasingly overweight populations.
Full text loading...
/content/article/0289-8020/33090/1371